Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Kite Pharma target raised to $95 at RBC Capital Mkts (72.53)RBC Capital Mkts raises their KITE tgt to $95 from $85. With the recent rally, they've fielded a number of incoming calls particularly from new investors looking at the KITE story for 2017. Discussions focus primarily around (1) sentiment and catalysts, (2) upcoming competitive data risk from NVS/Juno, and (3) commercial launch execution. They reiterate their Outperform, Speculative Risk, and built an interactive *KITE-APP* which suggests even conservative patients/site supports strong launch potential.</td> </tr></table>"